327 related articles for article (PubMed ID: 9570338)
1. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa.
Yoshigae Y; Imai T; Aso T; Otagiri M
Life Sci; 1998; 62(14):1231-41. PubMed ID: 9570338
[TBL] [Abstract][Full Text] [Related]
2. Species differences in stereoselective hydrolase activity in intestinal mucosa.
Yoshigae Y; Imai T; Horita A; Matsukane H; Otagiri M
Pharm Res; 1998 Apr; 15(4):626-31. PubMed ID: 9587961
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective hydrolysis of O-isovaleryl propranolol and its influence on the clearance of propranolol after oral administration.
Shameem M; Imai T; Yoshigae Y; Sparreboom A; Otagiri M
J Pharm Sci; 1994 Dec; 83(12):1754-7. PubMed ID: 7891307
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration.
Imai T; Yoshigae Y; Hosokawa M; Chiba K; Otagiri M
J Pharmacol Exp Ther; 2003 Dec; 307(3):1234-42. PubMed ID: 14534358
[TBL] [Abstract][Full Text] [Related]
5. Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine.
Ohura K; Soejima T; Nogata R; Adachi Y; Ninomiya S; Imai T
J Pharm Sci; 2012 Sep; 101(9):3264-74. PubMed ID: 22628163
[TBL] [Abstract][Full Text] [Related]
6. Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma.
Yoshigae Y; Imai T; Taketani M; Otagiri M
Chirality; 1999; 11(1):10-3. PubMed ID: 9914648
[TBL] [Abstract][Full Text] [Related]
7. Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.
Cook CS; Karabatsos PJ; Schoenhard GL; Karim A
Pharm Res; 1995 Aug; 12(8):1158-64. PubMed ID: 7494828
[TBL] [Abstract][Full Text] [Related]
8. Species differences for stereoselective hydrolysis of propranolol prodrugs in plasma and liver.
Yoshigae Y; Imai T; Horita A; Otagiri M
Chirality; 1997; 9(7):661-6. PubMed ID: 9366026
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective oral bioavailability of 0-isovaleryl propranolol as a potential prodrug of propranolol.
Shameem M; Imai T; Otagiri M
J Pharmacobiodyn; 1992 Sep; 15(9):535-40. PubMed ID: 1287187
[TBL] [Abstract][Full Text] [Related]
10. Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues.
Takahashi K; Tamagawa S; Sakano H; Katagi T; Mizuno N
Biol Pharm Bull; 1995 Oct; 18(10):1401-4. PubMed ID: 8593445
[TBL] [Abstract][Full Text] [Related]
11. First-pass hydrolysis of a propranolol ester derivative in rat small intestine.
Masaki K; Taketani M; Imai T
Drug Metab Dispos; 2006 Mar; 34(3):398-404. PubMed ID: 16326813
[TBL] [Abstract][Full Text] [Related]
12. An in-vitro and in-vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol.
Shameem M; Imai T; Otagiri M
J Pharm Pharmacol; 1993 Apr; 45(4):246-52. PubMed ID: 8098362
[TBL] [Abstract][Full Text] [Related]
13. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds.
Chan OH; Schmid HL; Stilgenbauer LA; Howson W; Horwell DC; Stewart BH
Pharm Res; 1998 Jul; 15(7):1012-8. PubMed ID: 9688053
[TBL] [Abstract][Full Text] [Related]
15. Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist.
Aungst BJ; Blake JA; Rogers NJ; Saitoh H; Hussain MA; Ensinger CL; Pruitt JR
Pharm Res; 1995 May; 12(5):763-7. PubMed ID: 7479565
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of stereoselective transdermal transport and concurrent cutaneous hydrolysis of several ester prodrugs of propranolol: mechanism of stereoselective permeation.
Ahmed S; Imai T; Otagiri M
Pharm Res; 1996 Oct; 13(10):1524-9. PubMed ID: 8899845
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
Shaw JP; Sueoko CM; Oliyai R; Lee WA; Arimilli MN; Kim CU; Cundy KC
Pharm Res; 1997 Dec; 14(12):1824-9. PubMed ID: 9453075
[TBL] [Abstract][Full Text] [Related]
18. Stereospecific activity and nature of metabolizing esterases for propranolol prodrug in hairless mouse skin, liver and plasma.
Ahmed S; Imai T; Yoshigae Y; Otagiri M
Life Sci; 1997; 61(19):1879-87. PubMed ID: 9364192
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the role of intestinal and liver metabolism in the conversion of two different ester prodrugs of sanfetrinem to the parent drug in vitro and in vivo using different rat tissues and a surgically prepared rat model.
Braggio S; Ferrara A; Sartori M; Bottacini M; Zanelli U; Zonzini L; Petrone M
Eur J Pharm Sci; 2002 Jul; 16(1-2):45-51. PubMed ID: 12113890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
